A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

Cancer

Volumn 98, Issue 2, 2003, Pages 310-314

  Younes, Anas ^a   Romaguera, Jorge ^a   Hagemeister, Frederick ^a   McLaughlin, Peter ^a   Rodriguez, Maria Alma ^a   Fiumara, Paolo ^a   Goy, Andre ^a   Jeha, Sima ^a   Manning Jr , John T ^a   Jones, Dan ^a   Abruzzo, Lynne V ^a   Medeiros, L Jeffrey ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti CD20; Interleukin 6 (IL 6); Monoclonal antibody; Reed Sternberg cells

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; DACARBAZINE; DOXORUBICIN; GAMMA INTERFERON; IFOSFAMIDE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; MUSTARD GAS; PREDNISONE; PROCARBAZINE; RITUXIMAB; STEROID; VINBLASTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HODGKIN DISEASE; HUMAN; LYMPH NODE; LYMPHOCYTE DEPLETION; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RECURRENT CANCER; SCLEROSIS; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; TREATMENT OUTCOME;

EID: 0038345400     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11511     Document Type: Article

References (27)

1. Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma. 1997;27:195-205.
2. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1-14.
3. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood. 1995;85:780-789.
4. Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001;98:2784-2790.
5. Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol. 2001;113:265-274.
6. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994; 83:2045-2056.
7. Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol. 1995;25:2083-2089.
8. Gruss HJ, Ulrich D, Dower SK, Herrmann F, Brach MA. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factor. Blood. 1996;87:2443-2449.
9. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol. 1995;147:912-922.
10. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73:1349-1360.
11. Clodi K, Asgari Z, Younes M, et al. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer. 2002;94:1-5.
12. Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood. 1997;89:2048-2059.
13. Younes A, Consoli U, Zhao S, et al. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol. 1996;93:569-571.
14. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2-9.
15. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27:79-85.
16. Watanabe K, Yamashita Y, Nakayama A, et al. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology. 2000;36:353-361.
17. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood. 1999;94:3108-3113.
18. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20:1278-1287.
19. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte predominant Hodgkin disease: results of a Phase II trial. Proc Am Soc Clin Oncol. 2002;21:1052a.
20. Gorschluter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol. 1995;6:477-482.
21. Hsu SM, Xie SS, Hsu PL, Waldron JA Jr. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease. Am J Pathol. 1992;141:129-138.
22. Pinto A, Gattei V, Zagonel V, et al. Hodgkin's disease: a disorder of dysregulated cellular cross-talk. Biotherapy. 1998;10:309-320.
23. Sarris AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999;10:433-440.
24. Serrano D, Ghiotto F, Roncella S, et al. The patterns of IL2, IFN-gamma, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar. Haematologica. 1997;82:542-549.
25. Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience. Med Oncol. 2000;17:59-63.
26. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97:250-255.
27. Fiumara P, Cabanillas F, Younes A. Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. Blood. 2001;98:2877-2878.